PT  - JOURNAL ARTICLE
AU  - Barnett, Brian S.
AU  - Mauney, Erin E.
AU  - King, Franklin
TI  - Psychedelic-assisted therapy: An overview for the internist
AID  - 10.3949/ccjm.92a.24032
DP  - 2025 Mar 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 171--180
VI  - 92
IP  - 3
4099  - http://www.ccjm.org/content/92/3/171.short
4100  - http://www.ccjm.org/content/92/3/171.full
SO  - Cleve Clin J Med2025 Mar 01; 92
AB  - Preliminary evidence suggests that psychedelic-assisted therapy—the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin—may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid diethylamide designated breakthrough therapies by the US Food and Drug Administration (FDA). However, in August 2024, the FDA declined to approve a New Drug Application for MDMA and asked its sponsor to conduct another phase 3 trial. Clinicians are urged to prepare for the possible return of psychedelics to medicine.